<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7334067</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7334067.1</article-id>
        <article-id pub-id-type="pmcaid">7334067</article-id>
        <article-id pub-id-type="pmcaiid">7334067</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1580358</article-id>
        <article-id pub-id-type="pmid">32220891</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0168</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1580358</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1580358</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Stopsack</surname>
              <given-names initials="KH">Konrad H.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nandakumar</surname>
              <given-names initials="S">Subhiksha</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wibmer</surname>
              <given-names initials="AG">Andreas G.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Haywood</surname>
              <given-names initials="S">Samuel</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Weg</surname>
              <given-names initials="ES">Emily S.</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Barnett</surname>
              <given-names initials="ES">Ethan S.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kim</surname>
              <given-names initials="CJ">Chloe J.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Carbone</surname>
              <given-names initials="EA">Emily A.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Vasselman</surname>
              <given-names initials="SE">Samantha E.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nguyen</surname>
              <given-names initials="B">Bastien</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hullings</surname>
              <given-names initials="MA">Melanie A.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Scher</surname>
              <given-names initials="HI">Howard I.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Morris</surname>
              <given-names initials="MJ">Michael J.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kantoff</surname>
              <given-names initials="PW">Philip W.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A8">8</xref>
            <xref rid="FN1" ref-type="author-notes">#</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Abida</surname>
              <given-names initials="W">Wassim</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A8">8</xref>
            <xref rid="FN1" ref-type="author-notes">#</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A2"><label>2</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A3"><label>3</label>Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A4"><label>4</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A5"><label>5</label>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A6"><label>6</label>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A7"><label>7</label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A8"><label>8</label>Weill Cornell Medical College, New York, NY</aff>
        <author-notes>
          <corresp id="CR1"><italic toggle="yes">Correspondence:</italic> Philip W. Kantoff or Wassim Abida, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, <email>kantoff@mskcc.org</email> or <email>abidam@mskcc.org</email></corresp>
          <fn fn-type="other" id="FN1">
            <label>#</label>
            <p id="P1">(co-senior authors)</p>
          </fn>
          <fn fn-type="COI-statement" id="FN2">
            <p id="P34">Conflicts of Interest</p>
            <p id="P35">H.S.: Consultancy/Advisory Board: Ambry Genetics Corporation, Konica Minolta, Inc. (compensated), WCG Oncology Advisory Board (compensated), Amgen (uncompensated), Bayer (Uncompensated) ESSA Pharma Inc (uncompensated), Janssen Research &amp; Development, LLC (Uncompensated), Janssen Biotech, Inc. (Uncompensated), OncLive Insights (Compensated), Menarini Silicon Biosystems (Uncompensated), Physicians Education Resource (Compensated), Sanofi Aventis (Uncompensated), Research funding: Epic Sciences, Janssen, Menarini Silicon Biosystemis, ThermoFisher Scientific, Travel, Accomodations, Expenses: Amgen, ESSA Pharma Inc., Genome Profiling, LLC, Menarini Silicon Biosystems, OncLive Insights, Physician Education Resource, Sanofi Aventis, WCG Oncology</p>
            <p id="P36">M.J.M.: Unpaid consultant: Astellas, Bayer, Endocyte; Paid consultant: Advanced Accelerator Applications, Blue Earth Diagnostics, Tokai, Tolmar, Oric; Institutional research funding: Bayer, Sanofi, Endocyte, Progenics, Corcept, Roche/Genentech</p>
            <p id="P37">D.B.S.: Consulting or honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina and Vivideon Therapeutics.</p>
            <p id="P38">P.W.K.: Investment in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences, and Tarveda Therapeutics. Company board member for Context Therapeutics LLC. Consultant/scientific advisory board member for Bavarian Nordic Immunotherapeutics, DRGT, GE Healthcare, Janssen, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics, and Thermo Fisher. Data safety monitoring boards for Genentech/Roche and Merck.</p>
            <p id="P39">W.A.: Consulting for Clovis Oncology, Janssen Pharmaceutica, MORE Health and ORIC Pharmaceuticals. Research funding from AstraZeneca, Zenith Epigenetics, Clovis Oncology and GlaxoSmithKline. Travel from Clovis Oncology, GlaxoSmithKline, and ORIC Pharmaceuticals.</p>
            <p id="P40">All other authors disclose no conflicts of interest.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>27</day>
          <month>3</month>
          <year>2020</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>01</day>
          <month>7</month>
          <year>2020</year>
        </pub-date>
        <volume>26</volume>
        <issue>13</issue>
        <issue-id pub-id-type="pmc-issue-id">360726</issue-id>
        <fpage>3230</fpage>
        <lpage>3238</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>09</day>
              <month>04</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-07-29 21:25:14.007">
              <day>29</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1580358.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Background:</title>
            <p id="P2">The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear.</p>
          </sec>
          <sec id="S2">
            <title>Methods:</title>
            <p id="P3">In patients with metastatic castration-sensitive prostate cancer at a tertiary referral center, clinical-grade targeted tumor sequencing was performed to quantify tumor DNA copy number alterations and alterations in predefined oncogenic signaling pathways. Disease volume was classified as high-volume (≥4 bone metastases or visceral metastases) <italic toggle="yes">vs.</italic> low-volume.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P4">Among 424 patients (88% white), 213 (50%) had high-volume disease and 211 (50%) had low-volume disease; 275 (65%) had <italic toggle="yes">de-novo</italic> metastatic disease and 149 (35%) had metastatic recurrence of non-metastatic disease. Rates of castration resistance (adjusted hazard ratio, 1.84; 95% CI, 1.40–2.41) and death (adjusted hazard ratio, 3.71; 95% CI, 2.28–6.02) were higher in high-volume disease. Tumors from high-volume disease had more copy number alterations. The NOTCH, cell cycle, and epigenetic modifiers pathways were the highest-ranking pathways enriched in high-volume disease. <italic toggle="yes">De-novo</italic> metastatic disease differed from metastatic recurrences in the prevalence of <italic toggle="yes">CDK12</italic> alterations but had similar prognosis. Rates of castration resistance differed 1.5-fold to 5-fold according to alterations in <italic toggle="yes">AR</italic>, <italic toggle="yes">SPOP</italic> (inverse), and <italic toggle="yes">TP53</italic>, and the cell cycle, WNT (inverse), and MYC pathways, adjusting for disease volume and other genomic pathways. Overall survival rates differed 2-fold to 4-fold according to <italic toggle="yes">AR, SPOP</italic> (inverse), WNT (inverse), and cell cycle alterations. PI3K pathway alterations were not associated with prognosis once adjusted for other factors.</p>
          </sec>
          <sec id="S4">
            <title>Conclusion:</title>
            <p id="P5">This study identified genomic features associated with prognosis in metastatic castration-sensitive disease that may aid in molecular classification and treatment selection.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>prostate cancer</kwd>
          <kwd>metastatic castration-sensitive</kwd>
          <kwd>panel sequencing</kwd>
          <kwd>genomic instability</kwd>
          <kwd>oncogenic signaling pathways</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
